Cargando…

Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report

OBJECTIVES: JC virus granule cell neuronopathy is a potentially fatal otherwise highly disabling disease without an approved therapeutic option. This case report presents the positive record to T-cell therapy in JC virus granule cell neuronopathy. METHODS: The patient represented with subacute cereb...

Descripción completa

Detalles Bibliográficos
Autores principales: Grote-Levi, Lea, Möhn, Nora, Bonifacius, Agnes, Tischer-Zimmermann, Sabine, Schweitzer, Finja, Mahmoudi, Nima, Silling, Steffi, Warnke, Clemens, Maecker-Kolhoff, Britta, Wattjes, Mike P., Eiz-Vesper, Britta, Höglinger, Günter U., Skripuletz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474852/
https://www.ncbi.nlm.nih.gov/pubmed/37385737
http://dx.doi.org/10.1212/NXI.0000000000200138
_version_ 1785100593439703040
author Grote-Levi, Lea
Möhn, Nora
Bonifacius, Agnes
Tischer-Zimmermann, Sabine
Schweitzer, Finja
Mahmoudi, Nima
Silling, Steffi
Warnke, Clemens
Maecker-Kolhoff, Britta
Wattjes, Mike P.
Eiz-Vesper, Britta
Höglinger, Günter U.
Skripuletz, Thomas
author_facet Grote-Levi, Lea
Möhn, Nora
Bonifacius, Agnes
Tischer-Zimmermann, Sabine
Schweitzer, Finja
Mahmoudi, Nima
Silling, Steffi
Warnke, Clemens
Maecker-Kolhoff, Britta
Wattjes, Mike P.
Eiz-Vesper, Britta
Höglinger, Günter U.
Skripuletz, Thomas
author_sort Grote-Levi, Lea
collection PubMed
description OBJECTIVES: JC virus granule cell neuronopathy is a potentially fatal otherwise highly disabling disease without an approved therapeutic option. This case report presents the positive record to T-cell therapy in JC virus granule cell neuronopathy. METHODS: The patient represented with subacute cerebellar symptoms. Diagnosis of JC virus granule cell neuronopathy was made because of infratentorially accentuated brain volume atrophy shown by brain MRI and the detection of JC virus DNA in the CSF. RESULTS: Six doses of virus-specific T cells were administered. Within 12 months after therapy initiation, the patient showed clear clinical benefit with improvement of symptoms, and JC viral DNA load significantly declined. DISCUSSION: We present the case report of a positive response to T-cell therapy in JC virus granule cell neuronopathy, leading to an improvement of symptoms.
format Online
Article
Text
id pubmed-10474852
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104748522023-09-03 Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report Grote-Levi, Lea Möhn, Nora Bonifacius, Agnes Tischer-Zimmermann, Sabine Schweitzer, Finja Mahmoudi, Nima Silling, Steffi Warnke, Clemens Maecker-Kolhoff, Britta Wattjes, Mike P. Eiz-Vesper, Britta Höglinger, Günter U. Skripuletz, Thomas Neurol Neuroimmunol Neuroinflamm Clinical/Scientific Note OBJECTIVES: JC virus granule cell neuronopathy is a potentially fatal otherwise highly disabling disease without an approved therapeutic option. This case report presents the positive record to T-cell therapy in JC virus granule cell neuronopathy. METHODS: The patient represented with subacute cerebellar symptoms. Diagnosis of JC virus granule cell neuronopathy was made because of infratentorially accentuated brain volume atrophy shown by brain MRI and the detection of JC virus DNA in the CSF. RESULTS: Six doses of virus-specific T cells were administered. Within 12 months after therapy initiation, the patient showed clear clinical benefit with improvement of symptoms, and JC viral DNA load significantly declined. DISCUSSION: We present the case report of a positive response to T-cell therapy in JC virus granule cell neuronopathy, leading to an improvement of symptoms. Lippincott Williams & Wilkins 2023-06-29 /pmc/articles/PMC10474852/ /pubmed/37385737 http://dx.doi.org/10.1212/NXI.0000000000200138 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Clinical/Scientific Note
Grote-Levi, Lea
Möhn, Nora
Bonifacius, Agnes
Tischer-Zimmermann, Sabine
Schweitzer, Finja
Mahmoudi, Nima
Silling, Steffi
Warnke, Clemens
Maecker-Kolhoff, Britta
Wattjes, Mike P.
Eiz-Vesper, Britta
Höglinger, Günter U.
Skripuletz, Thomas
Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report
title Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report
title_full Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report
title_fullStr Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report
title_full_unstemmed Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report
title_short Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report
title_sort adoptive allogeneic t-cell therapy improves the clinical outcome of jc virus granule cell neuronopathy: a case report
topic Clinical/Scientific Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474852/
https://www.ncbi.nlm.nih.gov/pubmed/37385737
http://dx.doi.org/10.1212/NXI.0000000000200138
work_keys_str_mv AT grotelevilea adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT mohnnora adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT bonifaciusagnes adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT tischerzimmermannsabine adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT schweitzerfinja adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT mahmoudinima adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT sillingsteffi adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT warnkeclemens adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT maeckerkolhoffbritta adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT wattjesmikep adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT eizvesperbritta adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT hoglingergunteru adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport
AT skripuletzthomas adoptiveallogeneictcelltherapyimprovestheclinicaloutcomeofjcvirusgranulecellneuronopathyacasereport